Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 17/20 | 0.64 |
| ▸ | MAP4K1 | Q92918 | 11/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.54 |
| ▸ | KLK1 | P06870 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16880699 | 0.81 | KLKB1 (0.83) | KLKB1MAP4K1KLK1 | |
| SCHEMBL16881544 | 0.81 | KLKB1 (0.79) | KLKB1MAP4K1KLK1 | |
| SCHEMBL5735418 | 0.80 | CSNK2A1 (0.61) | KLKB1MAP4K1ROCK1KLK1 | |
| SCHEMBL17442617 | 0.79 | KLKB1 (1.00) | KLKB1MAP4K1KLK1 | |
| Hydrochloric Acid SCHEMBL16246816 | 0.79 | CSNK2A1 (0.59) | KLKB1MAP4K1ROCK1KLK1 | |
| SCHEMBL17442733 | 0.76 | KLKB1 (0.86) | KLKB1MAP4K1KLK1 | |
| SCHEMBL18371201 | 0.76 | KLKB1 (1.00) | KLKB1MAP4K1KLK1 | |
| SCHEMBL1568037 | 0.76 | FYN (0.52) | KLKB1MAP4K1 | |
| SCHEMBL16880457 | 0.76 | KLKB1 (0.72) | KLKB1MAP4K1KLK1 | |
| SCHEMBL17442821 | 0.76 | KLKB1 (0.85) | KLKB1MAP4K1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885ROCK1 1303/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885ROCK1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.